Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer

被引：14

作者：

Martin, Miguel ^{[1
]}

机构：

[1] Hosp Univ San Carlos, Serv Oncol Med, Madrid 28040, Spain

来源：

WOMENS HEALTH | 2006年 / 2卷 / 04期

关键词：

adjuvant chemotherapy; breast cancer; docetaxel; taxanes;

D O I：

10.2217/17455057.2.4.527

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The introduction of taxanes in the armamentarium against breast cancer in the 1990s has been one of the landmarks in the treatment of this disease. Docetaxel in particular is considered one of the most active cytotoxic agents in metastatic breast cancer and has also been tested as adjuvant postsurgical therapy in earlier stages. A regimen including docetaxel, doxorubicin and cyclophosphamide (the TAC regimen) was the first combination that demonstrated the efficacy of docetaxel in the adjuvant setting. This combination has been approved by regulatory agencies for adjuvant therapy of node-positive breast cancer and is presently used worldwide. TAC is more toxic than the traditional anthracycline-containing combinations, but many of its side effects can be ameliorated with colony-stimulating growth factor support.

引用

页码：527 / 537

页数：11

共 38 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2]

Abe O, 1998, LANCET, V352, P930

[3]

Au HJ, 2005, BREAST CANCER RES TR, V94, pS218

[4]

Berry DA, 2004, BREAST CANCER RES TR, V88, pS17

[5] CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J].

BONADONNA, G ;

VALAGUSSA, P ;

MOLITERNI, A ;

ZAMBETTI, M ;

BRAMBILLA, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :901-906

[6] Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer [J].

Brain, EGC ;

Bachelot, T ;

Serin, D ;

Kirscher, S ;

Graic, Y ;

Eymard, JC ;

Extra, JM ;

Combe, M ;

Fourme, E ;

Noguès, C ;

Rouëssé, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (19) :2367-2371

[7] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[8]

Eiermann W, 2005, BREAST CANCER RES TR, V94, pS62

[9] 2 MONTHS OF DOXORUBICIN-CYCLOPHOSPHAMIDE WITH AND WITHOUT INTERVAL REINDUCTION THERAPY COMPARED WITH 6 MONTHS OF CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN POSITIVE-NODE BREAST-CANCER PATIENTS WITH TAMOXIFEN-NONRESPONSIVE TUMORS - RESULTS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT B-15 [J].

FISHER, B ;

BROWN, AM ;

DIMITROV, NV ;

POISSON, R ;

REDMOND, C ;

MARGOLESE, RG ;

BOWMAN, D ;

WOLMARK, N ;

WICKERHAM, DL ;

KARDINAL, CG ;

SHIBATA, H ;

PATERSON, AHG ;

SUTHERLAND, CM ;

ROBERT, NJ ;

AGER, PJ ;

LEVY, L ;

WOLTER, J ;

WOZNIAK, T ;

FISHER, ER ;

DEUTSCH, M .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1483-1496

[10] Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients:: 10-year follow-up results of the French Adjuvant Study Group 01 trial [J].

Fumoleau, P ;

Kerbrat, P ;

Romestaing, P ;

Fargeot, P ;

Brémond, A ;

Namer, M ;

Schraub, S ;

Gaudier, MJ ;

Mihura, J ;

Monnier, A ;

Clavère, P ;

Serin, D ;

Seffert, P ;

Pourny, C ;

Facchini, T ;

Jacquin, JP ;

Sztermer, JF ;

Datchary, J ;

Ramos, R ;

Luporsi, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :298-305

← 1 2 3 4 →